Female mucopolysaccharidosis IIIA mice exhibit hyperactivity and a reduced sense of danger in the open field test

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Langford Smith, Alex ^a   Langford Smith, Kia J ^a   Jones, Simon A ^b   Wynn, Robert F ^c   Wraith, J E ^b   Wilkinson, Fiona L ^a   Bigger, Brian W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DISEASE CLASSIFICATION; EXPLORATORY BEHAVIOR; FEMALE; HAZARD; HYPERACTIVITY; IMMOBILIZATION; MALE; MAZE TEST; MOUSE; MUSCLE STRENGTH; NONHUMAN; OPEN FIELD BEHAVIOR; OPEN FIELD TEST; SANFILIPPO SYNDROME; SEX DIFFERENCE; WILD TYPE; AGING; ANIMAL; C57BL MOUSE; FEAR; HYPERKINESIA; INBREEDING; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME;

ANIMALIA; MUS;

AGING; ANIMALS; BEHAVIOR, ANIMAL; CIRCADIAN RHYTHM; EXPLORATORY BEHAVIOR; FEAR; FEMALE; HYPERKINESIS; INBREEDING; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MUCOPOLYSACCHARIDOSIS III; TIME FACTORS;

EID: 80054720144     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025717     Document Type: Article

References (53)

1. Heron B, Mikaeloff Y, Froissart R, Caridade G, Maire I, et al. (2011) Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece. American journal of medical genetics Part A 155A: 58-68.
2. Meyer A, Kossow K, Gal A, Muhlhausen C, Ullrich K, et al. (2007) Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A). Pediatrics 120: e1255-1261.
3. Valstar MJ, Neijs S, Bruggenwirth HT, Olmer R, Ruijter GJG, et al. (2010) Mucopolysaccharidosis type IIIA: Clinical spectrum and genotype-phenotype correlations. Annals of Neurology 68: 876-887.
4. Kresse H, (1973) Mucopolysaccharidosis 3 A (Sanfilippo A disease): deficiency of a heparin sulfamidase in skin fibroblasts and leucocytes. Biochem Biophys Res Commun 54: 1111-1118.
5. Kresse H, Neufeld EF, (1972) The Sanfilippo A corrective factor. Purification and mode of action. J Biol Chem 247: 2164-2170.
6. Scott HS, Blanch L, Guo XH, Freeman C, Orsborn A, et al. (1995) Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome. Nat Genet 11: 465-467.
7. Valstar M, Ruijter G, van Diggelen O, Poorthuis B, Wijburg F, (2008) Sanfilippo syndrome: A mini-review. Journal of Inherited Metabolic Disease 31: 240-252.
8. Malm G, Månsson JE, (2010) Mucopolysaccharidosis type III (Sanfilippo disease) in Sweden: clinical presentation of 22 children diagnosed during a 30-year period. Acta Pædiatrica 99: 1253-1257.
9. Fraser J, Wraith JE, Delatycki MB, (2002) Sleep disturbance in mucopolysaccharidosis type III (Sanfilippo syndrome): a survey of managing clinicians. Clin Genet 62: 418-421.
10. Bax MC, Colville GA, (1995) Behaviour in mucopolysaccharide disorders. Arch Dis Child 73: 77-81.
11. Cleary MA, Wraith JE, (1993) Management of mucopolysaccharidosis type III. Arch Dis Child 69: 403-406.
12. Fraser J, Gason AA, Wraith JE, Delatycki MB, (2005) Sleep disturbance in Sanfilippo syndrome: a parental questionnaire study. Arch Dis Child 90: 1239-1242.
13. Roberts AL, Rees MH, Klebe S, Fletcher JM, Byers S, (2007) Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA. Mol Genet Metab 92: 115-121.
14. Malinowska M, Wilkinson FL, Langford-Smith KJ, Langford-Smith A, Brown JR, et al. (2010) Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS ONE 5: e14192.
15. Malinowska M, Wilkinson FL, Bennett W, Langford-Smith KJ, O'Leary HA, et al. (2009) Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Molecular Genetics and Metabolism 98: 235-242.
16. Hemsley KM, Norman EJ, Crawley AC, Auclair D, King B, et al. (2009) Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs-a proof of principle study. Mol Genet Metab 98: 383-392.
17. Hemsley KM, Beard H, King BM, Hopwood JJ, (2008) Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice. Genes, Brain and Behavior 7: 740-753.
18. Hemsley KM, King B, Hopwood JJ, (2007) Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice. Mol Genet Metab 90: 313-328.
19. Savas PS, Hemsley KM, Hopwood JJ, (2004) Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA. Mol Genet Metab 82: 273-285.
20. Gliddon BL, Hopwood JJ, (2004) Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice. Pediatr Res 56: 65-72.
21. McIntyre C, Byers S, Anson DS, (2010) Correction of mucopolysaccharidosis type IIIA somatic and central nervous system pathology by lentiviral-mediated gene transfer. The journal of gene medicine 12: 717-728.
22. Lau AA, Hopwood JJ, Kremer EJ, Hemsley KM, (2010) SGSH gene transfer in mucopolysaccharidosis type IIIA mice using canine adenovirus vectors. Mol Genet Metab 100: 168-175.
23. Fraldi A, Hemsley K, Crawley A, Lombardi A, Lau A, et al. (2007) Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes. Hum Mol Genet 16: 2693-2702.
24. Langford-Smith KJ, Mercer J, Petty J, Tylee K, Church H, et al. (2011) Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases. Journal of inherited metabolic disease 34: 499-508.
25. Langford-Smith K, Arasaradnam M, Wraith JE, Wynn R, Bigger BW, (2010) Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice. Molecular Genetics and Metabolism 99: 269-274.
26. Bhaumik M, Muller VJ, Rozaklis T, Johnson L, Dobrenis K, et al. (1999) A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology 9: 1389-1396.
27. McGlynn R, Dobrenis K, Walkley SU, (2004) Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. J Comp Neurol 480: 415-426.
28. Arfi A, Richard M, Gandolphe C, Bonnefont-Rousselot D, Therond P, et al. (2011) Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of long-term aspirin treatment. Molecular genetics and metabolism 103: 18-25.
29. Gografe SI, Sanberg PR, Chamizo W, Monforte H, Garbuzova-Davis S, (2009) Novel pathologic findings associated with urinary retention in a mouse model of mucopolysaccharidosis type IIIB. Comparative medicine 59: 139-146.
30. Crawley AC, Gliddon BL, Auclair D, Brodie SL, Hirte C, et al. (2006) Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA. Brain Res 1104: 1-17.
31. The Jackson Laboratory Website Available: http://jaxmice.jax.org/strain/003780.html. Accessed 2011 Sep 12.
32. Hemsley KM, Hopwood JJ, (2005) Development of motor deficits in a murine model of mucopolysaccharidosis type IIIA (MPS-IIIA). Behav Brain Res 158: 191-199.
33. Lau AA, Crawley AC, Hopwood JJ, Hemsley KM, (2008) Open field locomotor activity and anxiety-related behaviors in mucopolysaccharidosis type IIIA mice. Behav Brain Res 191: 130-136.
34. Lau AA, Hannouche H, Rozaklis T, Hassiotis S, Hopwood JJ, et al. (2010) Allogeneic stem cell transplantation does not improve neurological deficits in mucopolysaccharidosis type IIIA mice. Experimental neurology 225: 445-454.
35. Hemsley KM, Luck AJ, Crawley AC, Hassiotis S, Beard H, et al. (2009) Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease. The European journal of neuroscience 29: 1197-1214.
36. Langford-Smith A, Malinowska M, Langford-Smith KJ, Wegrzyn G, Jones S, et al. (2011) Hyperactive behaviour in the mouse model of mucopolysaccharidosis IIIB in the open field and home cage environments. Genes, Brain and Behavior 10: 673-682.
37. Simon P, Dupuis R, Costentin J, (1994) Thigmotaxis as an index of anxiety in mice. Influence of dopaminergic transmissions. Behav Brain Res 61: 59-64.
38. McIntyre C, Derrick Roberts AL, Ranieri E, Clements PR, Byers S, et al. (2008) Lentiviral-mediated gene therapy for murine mucopolysaccharidosis type IIIA. Mol Genet Metab 93: 411-418.
39. Voikar V, Polus A, Vasar E, Rauvala H, (2005) Long-term individual housing in C57BL/6J and DBA/2 mice: assessment of behavioral consequences. Genes, brain, and behavior 4: 240-252.
40. Arndt SS, Laarakker MC, van Lith HA, van der Staay FJ, Gieling E, et al. (2009) Individual housing of mice-impact on behaviour and stress responses. Physiology & behavior 97: 385-393.
41. Cressant A, Desmaris N, Verot L, Brejot T, Froissart R, et al. (2004) Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. J Neurosci 24: 10229-10239.
42. Li HH, Yu WH, Rozengurt N, Zhao HZ, Lyons KM, et al. (1999) Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase. Proc Natl Acad Sci U S A 96: 14505-14510.
43. Fu H, Kang L, Jennings JS, Moy SS, Perez A, et al. (2007) Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice. Gene Ther 14: 1065-1077.
44. Canal MM, Wilkinson FL, Cooper JD, Ed Wraith J, Wynn R, et al. (2010) Circadian rhythm and suprachiasmatic nucleus alterations in the mouse model of mucopolysaccharidosis IIIB. Behav Brain Res 209: 212-220.
45. Benjamini Y, Lipkind D, Horev G, Fonio E, Kafkafi N, et al. (2010) Ten ways to improve the quality of descriptions of whole-animal movement. Neuroscience and biobehavioral reviews 34: 1351-1365.
46. Crawley JN, (2007) What's wrong with my mouse?: behavioral phenotyping of transgenic and knockout mice Hoboken, NJ John Wiley pp. xvi, 523.
47. Lamberty Y, Gower AJ, (1996) Arm width and brightness modulation of spontaneous behaviour of two strains of mice tested in the elevated plus-maze. Physiology & behavior 59: 439-444.
48. Voikar V, Vasar E, Rauvala H, (2004) Behavioral alterations induced by repeated testing in C57BL/6J and 129S2/Sv mice: implications for phenotyping screens. Genes, brain, and behavior 3: 27-38.
49. Fu H, DiRosario J, Kang L, Muenzer J, McCarty DM, (2010) Restoration of central nervous system alpha-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type 2 vector delivery. The journal of gene medicine 12: 624-633.
50. Heldermon CD, Hennig AK, Ohlemiller KK, Ogilvie JM, Herzog ED, et al. (2007) Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B. PLoS ONE 2: e772.
51. Heldermon CD, Ohlemiller KK, Herzog ED, Vogler C, Qin E, et al. (2010) Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB. Mol Ther 18: 873-880.
52. Kafkafi N, Lipkind D, Benjamini Y, Mayo CL, Elmer GI, et al. (2003) SEE locomotor behavior test discriminates C57BL/6J and DBA/2J mouse inbred strains across laboratories and protocol conditions. Behavioral neuroscience 117: 464-477.
53. Gerlai R, (1996) Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype? Trends in neurosciences 19: 177-181.